Download pdf
Analysis of Financial Performances for REGENERON: Comparison with AMGEN, GILEAD, and BIOGEN
- 1 Beijing Chaoyang KaiWen Academy, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
As a matter of fact, plenty of biomedicne companies are grown faster especially after the impact of Covid. This paper analyzes the financial performance of REGENERON in comparison to its peers AMGEN, GILEAD, and BIOGEN. The study reveals that REGENERON exhibits robust financial health, characterized by a high and steadily rising gross margin throughout 2023, a revenue growth rate of 7.76%, and strong profitability driven by its popular Eylea series in the ophthalmology market. Conversely, GILEAD faces significant challenges, including declining gross margins, stagnant revenue, and unfavorable investment metrics such as a negative PEG ratio and increased P/E ratio. AMGEN shows stable performance with moderate growth, while BIOGEN struggles with lower profitability and fluctuating financial metrics. According to the results, REGENERON is well-positioned for continued growth, provided it maintains operational efficiency and adapts to competitive market dynamics. This research offers critical insights into the financial strategies and market positions of leading biopharmaceutical companies, serving as a valuable guide for investors and stakeholders in making informed decisions in a rapidly evolving industry.
Keywords
Comparative analysis, pharmaceutical industry, biotechnology companies, financial metrics, profitability comparison
[1]. Dushnitsky, G. (2006) When does corporate venture capital investment create firm value? Journal of Business Venturing, 21(6), 753-772.
[2]. Dushnitsky, G. (2012) Corporate venture capital in the twenty-first century: An integral part of firms’ innovation toolkit. In C. Douglas (Ed.), The Oxford Handbook of Venture Capital, 156-210.
[3]. Hill, S.A. and Birkinshaw, J. (2014) Ambidexterity and survival in corporate venture units. Journal of Management, 40, 1899-1931.
[4]. Gompers, P.A. (2002) Corporations and the financing of innovation: The corporate venturing experience. Economic Review, 87(4), 1-17.
[5]. McCammon, M.G., Pio, E., Barakat, S., et al. (2014) Corporate venture capital and Cambridge. Nature Biotechnology, 32(10), 975-978.
[6]. Tong, T.W. and Li, Y. (2011) Real options and investment mode: Evidence from corporate venture capital and acquisition. Organization Science, 22(3), 659-674.
[7]. Galloway, T.L. (2017) Exploring the innovation strategies of young firms: Corporate venture capital and venture capital impact on alliance innovation strategy. Journal of Business Research, 71, 55-65.
[8]. Gong, K. (2019) Amgen Medical: Pioneer of the Surgical "Magic Tool" Electromagnetic Knife.
[9]. Handler, A., Singh, M., Narro, J., Caamano, M. and Chan-Lau, J. A. (2009) Risk factors definition. Retrieved from https://www.risk.net/definition/risk-factors](https://www.risk.net/definition/risk-factors.
[10]. Graham, J.R., Smart, S.B. and Megginson, W.J. (2010) Corporate Finance (3rd ed.). Mason, OH: South-Western Cengage Learning.
[11]. Fernandes, N. (2014). Finance for executives: A practical guide for managers. NPV Publishing.
Cite this article
Yan,H. (2024). Analysis of Financial Performances for REGENERON: Comparison with AMGEN, GILEAD, and BIOGEN. Advances in Economics, Management and Political Sciences,107,1-9.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICFTBA 2024 Workshop: Finance's Role in the Just Transition
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).